yes... and almost hilariously B has already demonstrated non-inferiority to the current standard of care with a shorter dosing protocol... B is alreay a hit in a p2 trial... at least a single to extend the inning... now we will see in p2b if it can be stretched into a double to put the winning run in scoring position...
...for any with a basis of two or less... it is my opinion that the risk here is significantly mitigated...
Market Data 
Markets 
AI
